Investigational immunotherapy drug well tolerated in those with rare form of melanoma

Posted by on June 6, 2016 2:08 pm
Categories: health

An investigational immunotherapy drug being tested in the treatment of a rare form of skin cancer known as Merkel cell carcinoma has been found to be well tolerated with a clinical benefit seen in up to 42 percent of patients who failed prior treatment and were observed for at least six months.

Leave a Reply

Your email address will not be published. Required fields are marked *